

# USING ACETONITRILE AND TETRAHYDROFURAN INSTEAD OF N,N-DIMETHYLFORMAMIDE IN PEPTIDE BOND FORMATION





<u>Yahya E. Jad</u>,<sup>a</sup> Gerardo A. Acosta,<sup>b</sup> Sherine N. Khattab,<sup>c</sup> <u>Beatriz G. de la Torre</u>,<sup>a,d</sup> Thavendran Govender,<sup>a</sup> Hendrik G. Kruger,<sup>a</sup> Ayman El-Faham,<sup>c,e</sup> and Fernando Albericio<sup>a,b,d,f,g</sup>

<sup>a</sup> Catalysis and Peptide Research Unit, School of Health Sciences, University of Kwazulu-Natal, Durban 4001, South Africa, <sup>b</sup> Institute for Research in Biomedicine and CIBER-BBN, Barcelona 08028, Spain, <sup>c</sup> Department of Chemistry Faculty of Science, Alexandria University, P.O. Box 426, Ibrahimia, Alexandria 21321, Egypt, <sup>d</sup> School of Chemistry, Yachat Tech, Yachay City of Knowledge, 100119-Urcuqui, Ecuador, <sup>e</sup> Department of Chemistry, College of Science King Saud University, P.O. Box 2455, Riyadh11451, Saudi Arabia, <sup>f</sup> School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa, <sup>g</sup> Department of Organic Chemistry, University of Barcelona, Barcelona,



08028, Spain. E-mail: <u>yahyajad@yahoo.com</u>, <u>beatriz.garcia@upf.edu</u>



#### Introdution

In our opinion, the practical implantation of the synthetic methodologies used for peptide bond formation is very conservative. Either they have its roots into the tradition or even they are leadered by the designers of automatic synthesizers. The solvent used for all the synthetic process is a paradigm of that asseveration. Thus, during the 60's  $CH_2Cl_2$  (dichloromethane) was the reagent of choice for performing all solid-phase synthetic process. Then, DMF (*N*,*N*-dimethylformamide) and in less extension NMP (*N*-methyl-2-pyrrolidone) are the only solvents used. In fact and according to a survey which was done by other group, about 83% of peptide bond formation was achieved by using DCM or DMF as a solvent. [1] However and waiting for the final implementation of the REACH, the search of different solvents than DMF and NMP is mandatory, because the use of these two will be restricted after REACH implementation.

Previous reports were published about classification of solvents on environmental point view. According to these studies, DMF and NMP were classified under the undesirable solvent. On the other hand, THF (tetrahydrofuran) and ACN (acetonitrile) were classified under the usable solvent. In fact, they reported that ACN can be a good replacement for dipolar aprotic solvents such as DMF, NMP and also DMA (*N*,*N*-dimethylacetamide).[1]

**Table 4**. Racemization studies on the solid-phase assembling of H-Gly-Cys-Phe-NH<sub>2</sub> (stepwise solid-phase synthesis).<sup>[a]</sup>

Entry	<b>Coupling reagent</b>	Resin	Solvent	DL/LL (%) <sup>[b]</sup>
1	DIC/HOBt	PS	DMF	0.5
2		ChemMatrix	THF	0.3
3		ChemMatrix	ACN	0.4
4	DIC/HOAt	PS	DMF	0.4
5		ChemMatrix	THF	0.2
6		ChemMatrix	ACN	0.3
7	DIC/OxymaPure	PS	DMF	0.3
8		ChemMatrix	THF	0.2
9		ChemMatrix	ACN	0.3
10	DIC/Oxyma-B	PS	DMF	0.3
11		ChemMatrix	THF	0.3
12		ChemMatrix	ACN	0.3
[a] Couplings injection with	s were performed 5 min preact n a pure LL and DL samples ont	ivation at room temperatu to reverse-phase HPLC.	are. [b] Retention times	s for each epimer were identified after co

Several years ago, one of us demonstrated that acetonitrile (ACN) could be a good alternative for DMF and NMP [2]. Herein, we are discussing a deeper study on the use of both ACN and THF in peptide synthesis, in both solid-phase and solution chemistries.



**Table 1**. Yield and racemization during the formation of Z-Phg-Pro-NH<sub>2</sub> (stepwise solution-phase synthesis).<sup>[a]</sup>

Entry	<b>Coupling reagent</b>	Solvent	Yield (%) <sup>b]</sup>	DL/LL (%) <sup>[c]</sup>
1	DIC/HOBt	DMF	94.3	11.0
2		THF	93.3	8.7
3		ACN	94.4	4.3
4	DIC/HOAt	DMF	91.5	3.9
5		THF	93.9	2.3
6		ACN	93.9	2.7
7	DIC/OxymaPure	DMF	94.4	0.9
8		THF	93.5	0.6
9		ACN	95.7	0.6
10	DIC/Oxyma-B	DMF	90.0	1.0
11		THF	94.5	1.1
12		ACN	95.0	0.3
Table 2.phase syn	Yield and racemization thesis). <sup>[a]</sup>	n during the form	nation of Z-Phe-Val-P	ro-NH <sub>2</sub> (segment solution-
Entry	<b>Coupling reagent</b>	Solvent	Yield (%) <sup>[b]</sup>	LDL/LLL (%) <sup>[c]</sup>
1	DIC/HOBt	DMF	96.2	14.8
2		THF	92.2	4.8
3		ACN	96.5	10.5
4	DIC/HOAt	DMF	97.6	5.9
5		THF	94.3	0.9
6		ACN	96.8	1.7
7	DIC/OxymaPure	DMF	91.9	7.7
8		THF	91.8	1.9
9		ACN	96.1	0.7
10	DIC/Oxyma-B	DMF	90.7	5.1
11		THF	88 0	22

#### Solid-phase peptide synthesis

**Table 5**. Percentage of tetrapeptide des-Aib (H-Tyr-Aib-Phe-Leu- $NH_2$ ) during solid-phase assembling of pentapeptide (H-Tyr-Aib-Aib-Phe-Leu- $NH_2$ ).<sup>[a]</sup>

Entry	Coupling reagent	Solvent	Penta	(%) des-Ai	b(%) <sup>[b]</sup>
1	DIC/HOBt	DMF	4.7	89.9	
2		THF	9.6	90.4	
3		ACN	12.4	89.9	
4	DIC/HOAt	DMF	18.2	78.5	
5		THF	45.9	54.1	
6		ACN	53.6	41.5	
7	DIC/OxymaPure	DMF	53.0	47.0	
8		THF	93.6	6.4	
9		ACN	91.8	8.2	
10	DIC/Oxyma-B	DMF	19.6	80.4	
11		THF	62.6	37.4	
12		ACN	70.3	29.7	
Entry	<b>Coupling reagent</b>	Solvent	Deca (%)	des-Aib(%)	Byproduct
1	DIC/HOBt				(%)
2		DMF	8.2	38.6	<b>(%)</b> 42.1
3		DMF THF	8.2 4.9	38.6 32.8	(%) 42.1 49.3
4		DMF THF ACN	8.2 4.9 7.1	38.6 32.8 46.3	(%) 42.1 49.3 31.3
5	DIC/HOAt	DMF THF ACN DMF	8.2 4.9 7.1 23.8	38.6 32.8 46.3 53.0	(%) 42.1 49.3 31.3 14.2
6	DIC/HOAt	DMF THF ACN DMF THF	8.2 4.9 7.1 23.8 26.5	38.6 32.8 46.3 53.0 56.7	(%) 42.1 49.3 31.3 14.2 12.2
0	DIC/HOAt	DMF THF ACN DMF THF ACN	8.2 4.9 7.1 23.8 26.5 33.7	38.6 32.8 46.3 53.0 56.7 51.3	(%) 42.1 49.3 31.3 14.2 12.2 12.9
7	DIC/HOAt DIC/OxymaPure	DMF THF ACN DMF THF ACN DMF	8.2 4.9 7.1 23.8 26.5 33.7 37.8	38.6 32.8 46.3 53.0 56.7 51.3 34.0	(%) 42.1 49.3 31.3 14.2 12.2 12.9 21.9
0 7 8	DIC/OxymaPure	DMF THF ACN DMF THF ACN DMF DMF THF	<ul> <li>8.2</li> <li>4.9</li> <li>7.1</li> <li>23.8</li> <li>26.5</li> <li>33.7</li> <li>37.8</li> <li>69.8</li> </ul>	38.6 32.8 46.3 53.0 56.7 51.3 34.0 26.8	(%) 42.1 49.3 31.3 14.2 12.2 12.9 21.9 3.4
0 7 8 9	DIC/HOAt DIC/OxymaPure	DMF THF ACN DMF THF ACN DMF THF THF	8.2 4.9 7.1 23.8 26.5 33.7 37.8 69.8 49.6	38.6 32.8 46.3 53.0 56.7 51.3 34.0 26.8 47.4	(%) 42.1 49.3 31.3 14.2 12.2 12.9 21.9 3.4 3.0
0       7       8       9       10	DIC/Oxyma-B	DMF THF ACN DMF THF ACN DMF THF ACN DMF	8.2 4.9 7.1 23.8 26.5 33.7 37.8 69.8 49.6 10.6	38.6 32.8 46.3 53.0 56.7 51.3 34.0 26.8 47.4 33.5	(%) 42.1 49.3 31.3 14.2 12.2 12.2 12.9 21.9 3.4 3.0 34.5
0 7 8 9 10 11	DIC/HOAt DIC/OxymaPure DIC/Oxyma-B	DMF THF ACN DMF THF ACN DMF THF ACN DMF DMF	<ul> <li>8.2</li> <li>4.9</li> <li>7.1</li> <li>23.8</li> <li>26.5</li> <li>33.7</li> <li>37.8</li> <li>69.8</li> <li>49.6</li> <li>10.6</li> <li>59.7</li> </ul>	38.6 32.8 46.3 53.0 56.7 51.3 34.0 26.8 47.4 33.5 10.7	<ul> <li>(%)</li> <li>42.1</li> <li>49.3</li> <li>31.3</li> <li>14.2</li> <li>12.2</li> <li>12.9</li> <li>21.9</li> <li>3.4</li> <li>3.0</li> <li>34.5</li> <li>18.3</li> </ul>

12		ACN	94.3	0.5	[a] Fmoc-RinkAmide-ChemMatrix resin and or coupling). [b] Deletion tetrapeptide (des-Aib) wa
[a] Couplin starting ma injection w	ngs were performed without pre terials and products were identi- ith a pure LLL and LDL sampl	activation at room tempera fied by injection of pure s es.	ature.[b] Conversion yie ample. [c] Retention tim	eld calculated by HPLC. Retention times of nes for each epimer were identified after co-	
	D ' 4' 4 1'	41 1.1 1	1 1		J ]
<b>Fable 3</b> . Racemization studies on the solid-phase assembling of H-Gly-Ser-Phe-NH <sub>2</sub> (stepwise solid-phase synthesis). <sup>[a]</sup>					We thank Yoav Luxembourg (]
Entry	<b>Coupling reagent</b>	Resin	Solvent	DL/LL (%) <sup>[b]</sup>	(2009SGR1024), and the Institution
1	DIC/HOBt	PS	DMF	3.3	(Spain); the National Research F
2		ChemMatrix	THF	0.3	care for their finalicial support (SC
3		ChemMatrix	ACN	0.4	
4	DIC/HOAt DIC/OxymaPure	PS	DMF	0.4	• Either THF or ACN rendered the
5		ChemMatrix	THF	0.2	<ul> <li>Using OxymaPure with THF or</li> </ul>
6		ChemMatrix	ACN	0.3	<ul><li>suppressor and then Oxyma-B.</li><li>Using THF or ACN in solid-pha glycol rendered the product in hi</li></ul>
7		PS	DMF	0.4	
8		ChemMatrix	THF	0.2	• Using THF or ACN in combinat
9		ChemMatrix	ACN	0.3	decapeptide, then Oxyma-B more
10	DIC/Oxyma-B	PS	DMF	0.3	
11		ChemMatrix	THF	0.2	[1] K. Alfonsi, J. Colberg, P. J. Dunn, T.
10		ChemMatrix	ACN	0.3	D. A. Perry, M. Stefaniak, Green Cha

a] Fmoc-RinkAmide-ChemMatrix resin and one hour coupling times were generally applied, except for Aib-Aib (two hour double coupling). [b] Deletion tetrapeptide (des-Aib) was identified by peak overlap in HPLC with an authentic sample obtained in solid phase.

### Acknowledgments

We thank Yoav Luxembourg (Luxembourg Ind.,) for his continuous support in this program. This work was funded in part by the CICYT (CTQ2012-30930), the Generalitat de Catalunya (2009SGR1024), and the Institute for Research in Biomedicine Barcelona (IRB Barcelona) (Spain); the National Research Foundation, the University of KwaZulu Natal; AsphenPharma care for their financial support (South Africa); and SENESCYT (Ecuador).

## Conclusions

- Either THF or ACN rendered the product in higher purity and less racemization level than DMF when using different peptide models in solution-phase or solid-phase peptide synthesis.
- Using OxymaPure with THF or ACN showed in most of the cases a superior racemization suppressor and then Oxyma-B.
- Using THF or ACN in solid-phase peptide synthesis in combination with a totally polyethylene glycol rendered the product in higher yield than DMF.
- Using THF or ACN in combination with OxymaPure gave the best result during solid-phase synthesis of some hindered peptide such as Aib-enkephaline pentapeptide and Aib-ACP decapeptide, then Oxyma-B more than HOAt. The worst result in this regard was HOBt.

## References

- K. Alfonsi, J. Colberg, P. J. Dunn, T. Fevig, S. Jennings, T. A. Johnson, H. P. Kleine, C. Knight, M. A. Nagy, D. A. Perry, M. Stefaniak, *Green Chem.*, 10, 31-36 (2008)
- [2] G. A. Acosta, M. del Fresno, M. Paradis-Bas, M. Rigau-DeLlobet, S. Côté, M. Royo, F. Albericio, J Pept Sci., 15, 629 (2009)